Clinical Overview
Social Anxiety Disorder (SAD), also known as social phobia, is characterized by intense fear or anxiety about social situations where the individual may be scrutinized by others, leading to significant avoidance behaviors and functional impairment. The disorder affects approximately 7% of adults annually and 12% over their lifetime, making it one of the most common anxiety disorders. Onset typically occurs in early adolescence, with women slightly more affected than men.
The DSM-5-TR defines social anxiety disorder as marked fear or anxiety about social situations where the individual is exposed to possible scrutiny by others, with fears that they will act in ways that will be negatively evaluated. The anxiety is out of proportion to the actual threat posed by the social situation and causes clinically significant distress or impairment in functioning. Individuals recognize their fear as excessive but feel unable to control it.
The 2025 understanding of social anxiety disorder emphasizes its neurobiological basis involving dysfunction in fear processing circuits, particularly the amygdala and prefrontal cortex, with alterations in serotonin, GABA, and dopamine neurotransmitter systems. Modern treatment approaches combine evidence-based psychotherapy, particularly cognitive-behavioral therapy and exposure therapy, with pharmacological interventions including SSRIs and SNRIs as first-line medications.
Key Symptoms & Presentations
Performance Anxiety
Intense fear of performing in front of others including public speaking, eating, writing, or using public restrooms, with worry about being judged, embarrassed, or humiliated by others observing their performance.
Social Interaction Fears
Marked anxiety about social interactions such as meeting new people, making conversation, dating, or attending social gatherings, often accompanied by fears of appearing awkward, boring, or socially incompetent.
Physical Symptoms
Blushing, sweating, trembling, rapid heartbeat, nausea, muscle tension, and voice trembling that occur in anticipation of or during social situations, often causing additional embarrassment and reinforcing avoidance behaviors.
Anticipatory Anxiety
Persistent worry and anxiety about upcoming social situations, often beginning days or weeks in advance, leading to extensive mental rehearsal, catastrophic thinking, and planning to avoid or escape social encounters.
Avoidance Behaviors
Systematic avoidance of feared social situations including declining invitations, avoiding eye contact, sitting in back rows, leaving events early, or using alcohol or drugs to cope with social situations.
Safety Behaviors
Subtle avoidance strategies used during social situations to reduce anxiety, such as over-preparing for conversations, avoiding controversial topics, staying close to familiar people, or using phones to appear busy.
Negative Self-Evaluation
Harsh self-criticism and negative interpretation of social interactions, assuming others judge them negatively, focusing on perceived social mistakes, and ruminating about social performance after events.
Functional Impairment
Significant interference with work, academic, or personal relationships due to social fears, including difficulty with job interviews, presentations, dating, making friends, or advancing in career due to social anxiety.
Treatment Approaches
Cognitive-Behavioral Therapy (CBT):
CBT is highly effective for social anxiety disorder, focusing on identifying and challenging negative thought patterns, gradual exposure to feared social situations, and developing coping strategies. Social skills training and assertiveness training are often incorporated to build confidence and improve social interactions.
Pharmacological Interventions:
SSRIs are first-line medications for social anxiety disorder, with sertraline, paroxetine, and fluvoxamine having FDA approval for this indication. Venlafaxine XR is the only SNRI with FDA approval for social anxiety disorder.
Performance Anxiety Management:
Propranolol (10-80 mg) taken 1-2 hours before specific performance situations can effectively reduce physical symptoms of anxiety, particularly useful for musicians, public speakers, or others with situational performance anxiety.
Combination and Intensive Treatments:
Combining medication with CBT often provides superior outcomes compared to either treatment alone. Group therapy specifically designed for social anxiety provides real-world exposure opportunities and peer support, while intensive programs may be beneficial for severe cases.
Medication Considerations
First-Line SSRI Medications:
Sertraline (Zoloft): 25-200 mg/day, FDA-approved for social anxiety disorder with excellent evidence base. Start at 25 mg to minimize activation, then increase to 50-100 mg/day for maintenance.
Paroxetine (Paxil): 10-60 mg/day, FDA-approved for social anxiety disorder with strong efficacy data. Higher risk of discontinuation syndrome requires careful tapering.
Fluvoxamine (Luvox): 50-300 mg/day, FDA-approved for social anxiety disorder but significant drug interactions via CYP450 inhibition require monitoring.
Other Effective SSRIs:
Escitalopram (Lexapro): 5-20 mg/day, not FDA-approved for social anxiety but strong evidence supports efficacy with excellent tolerability and low drug interaction potential.
Fluoxetine (Prozac): 10-60 mg/day, effective for social anxiety though may initially increase anxiety. Long half-life reduces withdrawal symptoms.
Citalopram (Celexa): 10-40 mg/day, effective option with good tolerability, though QTc monitoring required at higher doses.
SNRI Option:
Venlafaxine XR (Effexor): 37.5-225 mg/day, only SNRI with FDA approval for social anxiety disorder. Dual neurotransmitter activity may be beneficial, though monitor blood pressure at higher doses.
Performance Anxiety Medications:
Propranolol (Inderal): 10-80 mg taken 1-2 hours before performance situations. Beta-blocker that reduces physical symptoms (tremor, rapid heartbeat, sweating) without affecting cognitive function.
Atenolol: 25-100 mg, longer-acting beta-blocker alternative for performance anxiety, though less commonly used than propranolol.
Alternative and Adjunctive Options:
Buspirone (BuSpar): 15-60 mg/day divided doses, 5-HT1A partial agonist without sedation or dependence risk, though requires 4-6 weeks for full effect.
Pregabalin (Lyrica): 150-600 mg/day, evidence for social anxiety disorder though not FDA-approved for this indication. Rapid onset but sedation and weight gain concerns.
Medications to Use Cautiously:
Benzodiazepines: Clonazepam (0.25-2 mg/day) may be used short-term or as-needed, but dependence risk and potential interference with exposure therapy limit routine use.
Special Considerations:
Start SSRIs at lower doses to minimize initial activation that can worsen anxiety. Allow 8-12 weeks for full therapeutic effect. Beta-blockers are contraindicated in asthma and should be used cautiously with diabetes. Avoid alcohol which can worsen social anxiety long-term despite short-term anxiolytic effects.
Common Comorbidities
Condition
Clinical Considerations
Major Depressive Disorder
Present in 40-50% of individuals with social anxiety disorder, often developing secondary to social impairment and isolation. SSRIs like sertraline effectively treat both conditions simultaneously.
Other Anxiety Disorders
Generalized anxiety and panic disorder commonly co-occur with social anxiety. SSRIs provide broad-spectrum anxiety relief, though social-specific CBT remains essential for addressing avoidance behaviors and social skills deficits.
Alcohol Use Disorder
Affects 20-30% of individuals with social anxiety disorder, often used as self-medication before social situations. Requires integrated treatment with preference for SSRIs over benzodiazepines due to lower abuse potential.
Avoidant Personality Disorder
Pervasive pattern of social inhibition and inadequacy feelings that overlaps significantly with social anxiety disorder. May require longer treatment duration and intensive psychotherapy alongside medication management.
Autism Spectrum Disorder
Social communication difficulties in autism may be complicated by co-occurring social anxiety. Requires careful differential diagnosis and may benefit from sertraline or escitalopram for anxiety symptoms.
ADHD
Social difficulties in ADHD may be compounded by social anxiety about performance and rejection. Stimulant medications may initially worsen anxiety, requiring established SSRI treatment before stimulant initiation in some cases.
Body Dysmorphic Disorder
Excessive concern about physical appearance that drives social avoidance. May respond to higher doses of SSRIs like fluoxetine (40-80 mg/day) similar to OCD treatment approaches.
